The present invention relates to an antiparasitic composition comprising an antiparasitic agent and a semifluorinated alkane.

The present invention relates to an antiparasitic composition comprising an antiparasitic agent and a semifluorinated alkane.

Disclosed in the present invention is a lysosome-targeting antibody-drug conjugate and use thereof. The structure of the antibody-drug conjugate is Dr.sub.n1AbO.sub.n2; wherein, Dr is a drug, Ab is an antibody, and O is a lysosome-targeting small molecule or a functional peptide for increasing the lysosomal targeting ability of the antibody-drug conjugate; n1 and n2 are integers greater than or equal to 1, and n1 and n2 are identical or different.

Disclosed in the present invention is a lysosome-targeting antibody-drug conjugate and use thereof. The structure of the antibody-drug conjugate is Dr.sub.n1AbO.sub.n2; wherein, Dr is a drug, Ab is an antibody, and O is a lysosome-targeting small molecule or a functional peptide for increasing the lysosomal targeting ability of the antibody-drug conjugate; n1 and n2 are integers greater than or equal to 1, and n1 and n2 are identical or different.

The present disclosure provides methods for treating or preventing an infectious disease or condition, such as the COVID-19 virus (SARS-CoV-2), by administering a therapeutically effective amount of taxifolin to a subject in need thereof, wherein the taxifolin is administered to the subject in combination with a therapeutically effective amount of one or more additional therapeutic agents.

The present disclosure provides methods for treating or preventing an infectious disease or condition, such as the COVID-19 virus (SARS-CoV-2), by administering a therapeutically effective amount of taxifolin to a subject in need thereof, wherein the taxifolin is administered to the subject in combination with a therapeutically effective amount of one or more additional therapeutic agents.

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.

The invention provides methods, compositions, and medical kits comprising a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders and preservation of blood products. In one aspect, the invention provides methods, compositions, and medical kits comprising an inorganic nitrite salt and a nitrite-reductase promoter, such as an allosteric modulator of hemoglobin, for use in treating medical disorders, such as cancer, cardiovascular disorders, ischemic conditions, hemolytic conditions, and bacterial infections. Exemplary inorganic nitrite salts include sodium nitrite and arginine nitrite. Exemplary allosteric modulators of hemoglobin described herein include alkyl-substituted and acyl-substituted di-nitroheterocycles.